FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.